4 ms·
There's a history of drugs that reduced amyloid plaques, perhaps with even better efficiency than aducanumab (I don't recall exact details) yet still failed to
by jcranmer 5y ago
There's a history of drugs that reduced amyloid plaques, perhaps with even better efficiency than aducanumab (I don't recall exact details) yet still failed to demonstrate any effect on patient outcomes.
The commentary that the trials haven't "conclusively demonstrated any effect" is an understatement. Recall that one of the trials outright failed the endpoint, and the attempt to reconcile that with the other trial smells strongly of statistical hogwash. The advisory committee rejected it wholesale, with not a single vote in favor and only one vote not in disfavor (i.e., abstention).
- jasonlaramburu 5y agoMy understanding is that aducanumab has shown the greatest efficacy of any beta amyloid blocker (at reducing beta amyloid, with the least side effects. It definitely has side effects (brain swelling in 40%), but other Beta amyloid blockers have proven largely intolerable.